to summarize the issues and recommendations contained in this April 2010 analysis of graduate education. The Committee also considered the recently released report from the National Research Council which offers a data-based assessment of doctoral programs in 62 fields in the United States ii .
Background: The Path Forward
"The Path Forward" report focused on graduate education as defined by master's and doctoral programs and did not examine first-professional degrees, including the PharmD degree. It was a joint effort of the Educational Testing Service and the Council of Graduate Schools aimed at examining critical issues associated with the structure and well-being of graduate education in the US. It was undertaken at a point of great controversy regarding US competitiveness on a global economic stage and the role of education at all levels in assuring the country's continuing competitive position. A fundamental premise of the report is that US competitiveness "hinges on our ability to produce sufficient numbers of graduate-degree holders -people with the advanced knowledge and critical-thinking abilities to devise solutions to grand challenges such as energy independence, affordable health care, climate change and others."
Graduate education in the United States gained world class status during the 20 th century, attracting the most talented students from across the globe. Our programs are among those top ranked by several ranking systems and it is notable that from 1997 to 2009 over half the Nobel Prize winners in chemistry, physics, medicine and economics received their graduate degrees in the US. Graduates of master's and doctoral programs enjoy higher rates of employment and higher lifetime earnings than individuals with lower levels of education.
According to the report there are key points of vulnerability to the dominant US position in graduate education, including:
1. Competition from graduate education in other countries as governments in both developed and emerging economies work to strengthen their programs thereby attracting students who might otherwise have sought graduate degrees from US programs;
2. Demographic trends in the US indicate the greatest future growth in the population among those racial and ethnic groups who have historically been the least likely to pursue graduate education; 3. Attrition rates and time to completion in US doctoral programs, coupled with the increased cost burden and declining support for graduate education from public and private sources; and
4. An uncertain postgraduate job market with fulltime faculty positions disappearing and new skill sets becoming important to prospective employers in nonacademic positions.
Recommendations are articulated for three audiences -universities, corporations and policymakers.
These will be summarized briefly as they are germane to the discussion of the way forward for graduate programs in the pharmaceutical sciences.
Recommendations for Universities
• Improve degree completion rates -the Council of Graduate Schools is poised to release the work of the Ph.D. Completion Project which is critically examining issues associated with attrition and completion of doctoral programs. Individual programs and institutions should analyze their own completion rates and work to address the causes of attrition in both doctoral and master's programs; recently released National Research Council findings should inform these analyses;
• Clarify career pathways for graduate students -graduate programs should provide guidance for students on the diverse careers available to those with graduate education, including academia, business, government and nonprofit sectors. In addition, there are essential skills (such as those emphasized in emerging professional science master's degree programs) which should be incorporated into contemporary master's and doctoral degree granting programs to equip graduates with a competitive skill-base for postgraduate employment;
• Prepare future faculty -with the aging of the professoriate and national goals for increasing the proportion of the US population with college degrees by 2020, an emphasis must be placed on the preparation of individuals in graduate programs to become the next generation of outstanding faculty. CGS continues to emphasize the importance of its Preparing Future Faculty model launched in 1993 which reached 45 doctoral degree-granting institutions and almost 300
"partner" institutions across the US;
• Emphasize key professional development issues in graduates -as noted above, there are key skills often noted lacking in graduates of doctoral programs which are essential for 21 st century competitiveness: creativity and entrepreneurship, self-organization, project management skills, professional/research ethics, and teamwork, communications, and insights into how one's work relates to the broader context or social purposes;
• Enhance the pipeline -learn from existing successful programs (e.g., Meyerhoff Scholars
Program, McNair Post-baccalaureate Achievement Program) and link K-12, undergraduate and graduate programs to create clear pathways for students from all demographic groups to pursue advanced education and training.
Recommendations for Employers
• Provide financial support for graduate education -endowing graduate school chairs, creating "lifelong learning accounts" and tuition reimbursement programs, targeted programs supporting under-represented minorities, and industry-sponsored graduate fellowship programs;
• Collaborate with universities to clarify entry points into careers -clarifying the educational skills needed for 21 st century jobs so that educators can help students make informed judgments and plans about their educational pathways;
• Offer internships and work study opportunities for graduate students.
Recommendations for Policymakers • Create/fund innovative master's degree programs -in keeping with the recommendations for the professional science master's degree with skills focused on innovation, teamwork and competitiveness, funding should be created to stimulate the design/redesign of master's programs at 4-year institutions;
• Continue support in key areas -federal graduate training/fellowship programs, loan forgiveness programs for graduate students in priority fields, amend tax policies for graduate fellowships and scholarships, and align federal and state research and graduate grant programs;
• Address international student issues -improve the visa process to continue attracting outstanding graduate students from outside the US and retaining doctorates in science, technology, engineering and math (STEM) fields, create incentives for global collaborations with universities abroad, and encourage more US graduate students to engage in international experiences, such as the Fulbright or study abroad programs.
The Committee discussed the most obvious implications in "The Path Forward" report for pharmacy graduate programs. The percentage of graduate students with US pharmacy degrees has declined sharply in the past decade and many programs find their master's and doctoral programs populated by a majority of international students. The availability of funding for graduate programs is in jeopardy, especially in the face of state budget deficits and sharp declines in funding for higher education. Career pathways for graduates are also changing with employment prospects at the research intensive pharmaceutical companies declining in the face of major personnel reductions and shifts in the approach to the research enterprise by the shrinking number of corporations struggling to remain competitive. Faculty characteristics including items such as faculty demographics, publications per faculty, percentage of faculty with grants, and faculty activities. Two approaches were utilized to analyze the data, with different weights given to program and faculty characteristics. The S-rankings placed the greatest weight on faculty-related characteristics, while the R-rankings placed the greatest weight on program-related characteristics. The rankings were reported in broad ranges rather than as single numbers, reflecting uncertainties inherent in any effort to rank programs by quality.
National
The graduate programs in pharmacy such as pharmaceutical sciences, medicinal chemistry, pharmaceutics, and pharmacology were included in the larger specialization category of "Pharmacology, Toxicology, and Environmental Health." Pharmacy faculty were included in the NRC Faculty Surveys, and pharmacy graduate programs were included in the data collection by their universities. Although the NRC assessment does not provide a single ranking number for each program, the data and assessment tools enable faculty, current and prospective students, and administrators to examine program and faculty characteristics of importance to each. One weakness of the NRC assessment is that the data, gathered in 2006-07, may no longer be relevant due to changes in department faculty, student support services, and financial support over recent years.
Approximately 30 doctoral programs from schools/colleges of pharmacy participated in the NRC assessment. A total of 116 doctoral programs were included in the specialization category of "Pharmacology, Toxicology, and Environmental Health," with the majority being pharmacology programs in colleges of medicine and toxicology/environmental health programs in schools of public health. Examination of both the S-rankings and R-rankings find that the doctoral programs in colleges of pharmacy were distributed evenly throughout the upper to lower quartiles as indicated by the arrows in Appendices 1 and 2.
Additional Information on Evaluation of Graduate Programs at Colleges/Schools of Pharmacy
Given that explicit information about the quality of current graduate programs in colleges and schools of pharmacy is somewhat dated and difficult to derive from the NRC assessment, the RGAC embarked upon a query to AACP member institutions to provide additional insights into the evaluation of their programs.
A 5-question inquiry was sent to those identified as individuals with administrative responsibility for research and/or graduate education at US colleges and schools of pharmacy. The questions sought information on whether and how frequently graduate program reviews were undertaken, whether the reviews were conducted for all programs on campus and whether the review was conducted by a state authority (e.g., higher education office) or by the college/school independently of the university or other authority.
The responses provide insights into the nature and frequency of graduate program reviews though they could not be generalized to characterize all graduate programs given the nature of the query and limited number of responses. Of the 15 programs responding, all indicated that their master's and doctoral programs were reviewed on a frequency ranging from 4 to 10 years with a median frequency of every 5 to 7 years. Twelve of the 15 reporting program reviews were part of a campus-wide review process and none were conducted by state authorities. In three of 15 cases the school conducted its own reviews independent of the university.
Respondents were also asked to briefly describe the nature of the review process and/or send supportive materials describing the process. In general, programs engage in a self-study process and the reviews are conducted by external reviewers or by a combination of internal and external reviewers. A combination of qualitative and quantitative metrics appear to be used though generalization based on the information provided is difficult.
Two members of the RGAC were administrators at universities that evaluated their doctoral programs, including The Ohio State University (2008-09) and the University of Iowa (2009-10) . Since the doctoral program characteristics were gathered in the 2006-07 academic year for the NRC, this data provided the baseline and was supplemented by university-specific measures (such as graduate placement data and publications per student). External and internal faculty review teams evaluated the data and reports from the programs as part of the assessment processes. At both Iowa and Ohio State, the doctoral programs in pharmacy and pharmaceutical sciences were rated among the highest quality on the measures used by their respective universities.
Relevant Findings in Previous Research and Graduate Affairs Reports
Given that the AACP Bylaws specify that the Research and Graduate Affairs Committee is one of the Association's standing committees charged annually by the incoming president to study key issues, it is not surprising that several recent committee reports examine issues included in both "The Path Commons, which is defined as when a common resource that is available for use in the public domain by all is over exploited because there is an individual benefit, albeit to the ultimate detriment of both the common pool resource and its users. v,vi,vii The end result was an excess of biomedical science Ph.D.
graduates, which could result in graduates ending up in increasingly prolonged postdoctoral positions. A large supply of talented foreign/international students helped negate the role of market factors in moderating the demand for graduate education. Many of these students ended up in postdoctoral positions because US universities were stretching their resources by offering lower salaries than what might be otherwise possible. This exacerbated the trend of fewer US students selecting graduate education, and of those who did, many were poorly prepared for the rigors of a science-based career.
The authors offered examples of how colleges/schools of pharmacy could solve some of their problems.
Solutions included having an appropriately sized graduate program, looking for duplication, increasing stipends, shortening the time to degree completion, developing better mentoring systems, offering teaching experiences for graduate students, and offering dual degree programs such as the PharmD/Ph.D.. • There is more than one pathway of education/training that an individual can take to become a successful clinical scientist, but with the present focus on clinical training programs sponsored by NIH, such as the K awards and the Clinical and Translational Science Award (CTSA) program, a master's degree appears to be the minimally accepted pathway to becoming an independent clinical scientist.
• Attracting PharmD students to a clinical research career must begin early in the professional degree program, preferably that first professional year. The major obstacle to attracting students to clinical research however, is the lack of significant numbers of clinical researcher role models or mentors at many institutions. Curricular modifications such as tracking, summer research opportunities and dual degree programs can assist in attracting students, but most students are enticed into a research career by a faculty member whose career they wish to emulate and who These reports address key components of graduate education programs at US colleges and schools of pharmacy and offer important recommendations for AACP and its members. A number of those recommendations have been implemented but others, notably the need for better data collection and analysis on graduate education, remain to be implemented.
Analysis of Strengths, Weaknesses, Opportunities and Threats to Graduate Programs
With the background information provided by current and past reports, the Committee articulated key points of strength and weakness in US pharmaceutical sciences graduate education.
Strengths
• US pharmaceutical science graduate programs have been successful in attracting top international candidates to their programs
• Time to degree and completion rates are competitive with national data
• Student debt burdens reflect lower accumulation of debt than for other graduate students
• Graduates are competitive for available post-doctoral training positions (in those disciplines where post-doctoral training is common)
Weaknesses
• Increasing numbers of faculty who do not have degrees in pharmacy are not as equipped to envision career pathways for professional doctoral students
• Assumptions that PharmD students cannot be attracted to graduate programs in the pharmaceutical sciences blunt faculty efforts to find those exceptional students who could be recruited into programs
• Our faculty tend to shy away from advocacy efforts that draw attention to the significant accomplishments of our faculty and graduate students
• Faculty fail to communicate the full benefits of academic life to graduate and professional degree students Opportunities
• It is an excellent time to critically examine the career paths available to graduates of master's and doctoral programs in new biomedical companies, clinical research organizations, regulatory agencies, etc.
• Increased numbers of colleges and schools of pharmacy are recruiting faculty at US colleges and schools of pharmacy are not immune to these issues. The potential competition for international graduate students by other countries, the importance of interdisciplinary graduate education, and funding constraints are top among these considerations. A fresh examination of the career paths for graduates from master's and doctoral programs in the pharmaceutical sciences is warranted given the changes in the most significant employer in the past, the research intensive pharmaceutical companies.
Programs would also benefit from additional efforts to collect benchmarking information for meaningful assessment of program vitality and quality. The new AACP Graduate Education Special Interest Group will provide a forum for communication among those directing graduate programs at AACP member institutions that can guide future work to improve graduate education across the pharmaceutical sciences and keep our programs at their competitive best.
Recommendations of the 2010-11 Research and Graduate Affairs Committee
Recommendation 1: AACP should assist with recruitment of pharmacy and non-pharmacy students into graduate programs at member institutions by developing a centralized information portal on master's and doctoral programs that includes information on why students should consider graduate education, the characteristics and admissions policies of US programs, career pathway information and links to the Web sites of current programs. 
